Assessment of Whether the American Society of Clinical Oncology’s Value Framework and the European Society for Medical Oncology’s Magnitude of Clinical Benefit Scale Measure Absolute or Relative Clinical Survival Benefit-Reference-Cited by-同舟云学术

Assessment of Whether the American Society of Clinical Oncology’s Value Framework and the European Society for Medical Oncology’s Magnitude of Clinical Benefit Scale Measure Absolute or Relative Clinical Survival Benefit

Published:2019-08-01 Issue:8 Volume:5 Page:1188
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Saluja Ronak¹,Everest Louis¹,Cheng Sierra¹,Cheung Matthew¹²,Chan Kelvin K. W.¹²³⁴

Affiliation:

1. Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

2. Department of Medicine, University of Toronto, Toronto, Ontario, Canada

3. Canadian Centre for Applied Research in Cancer Control, Toronto, Ontario, Canada

4. Cancer Care Ontario, Toronto, Ontario, Canada

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/article-pdf/5/8/1188/17773624/jamaoncology_saluja_2019_oi_190022.pdf

Reference22 articles.

1. Updating the American Society of Clinical Oncology Value Framework: revisions and reflections in response to comments received.;Schnipper;J Clin Oncol,2016

2. ESMO-Magnitude of Clinical Benefit Scale version 1.1.;Cherny;Ann Oncol,2017

3. Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale measure the same construct of clinical benefit?;Cheng;J Clin Oncol,2017

4. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).;Cherny;Ann Oncol,2015

5. Exploration of the ASCO and ESMO value frameworks for antineoplastic drugs.;Becker;J Oncol Pract,2017

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Can cancer go green? It’s up to us;Frontiers in Oncology;2023-02-22

2. Validating Restricted Mean Survival Time Estimates From Reconstructed Kaplan-Meier Data Against Original Trial Individual Patient Data From Trials Conducted by the Canadian Cancer Trials Group;Value in Health;2022-07

3. Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China;PharmacoEconomics;2022-06-29

4. An Evaluation of Sex- and Gender-Based Analyses in Oncology Clinical Trials;JNCI: Journal of the National Cancer Institute;2022-04-27

5. Bayesian nonparametric analysis of restricted mean survival time;Biometrics;2022-02-02